Details of the Researcher

PHOTO

Airi Takagi
Section
Tohoku University Hospital
Job title
Assistant Professor
Degree
Profile

以前は企業のInnovator・技術者でしたが、携わった製品の臨床研究で医学統計に魅せられ、東北大学医学系研究科の医学統計学分野にて勉強し、博士号を取得しました。また、統計家としてデータセンターの臨床研究のデザインや解析に携わり、基本的な知識を身に付けました。
今後は、クリニカルデータサイエンスや医学統計分野において、独自の視点で新たな方法論を提唱することで、組織と医療技術の発展に寄与することが目標です。

Research History 3

  • 2024/04 - Present
    Department of Ophthalmology, Tohoku University Graduate School of Medicine

  • 2014/04 - 2024/03
    Department of Clinical Research Data Center, Tohoku University Hospital

  • 2006/04 - 2014/03
    Research & Development Center, Panasonic Healthcare Co., Ltd.

Education 3

  • Tohoku University　Graduate School of Medicine　Department of Medical Sciences

    2013/04 - 2017/03

  • Tohoku University　Graduate School of Environmental Studies

    2004/04 - 2006/03

  • Tohoku University　Faculty of Engineering

    2000/04 - 2004/03

Committee Memberships 1

  • 日本計量生物学会　実務試験統計家

    2020/04 - Present

Professional Memberships 2

  • 日本臨床試験学会

  • THE BIOMETRIC SOCIETY OF JAPAN

Research Interests 6

  • 医療情報管理学

  • 臨床品質マネジメント

  • biomedical engineering

  • Medical Statistics

  • 臨床研究

  • Biostatistics

Research Areas 5

  • Informatics / Biological, health, and medical informatics /

  • Life sciences / Medical equipment testing /

  • Life sciences / Biomedical engineering /

  • Life sciences / Healthcare management, medical sociology /

  • Informatics / Statistical science /

Papers 18

  1. Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings. Peer-reviewed

    Chiaki Yamaguchi, Noriko Himori, Naoki Kiyota, Tatsuro Misu, Kimihiko Kaneko, Airi Takagi, Kotaro Suzuki, Yuki Matsumoto, Takahiro Ninomiya, Satoru Tsuda, Masashi Aoki, Toru Nakazawa

    Japanese journal of ophthalmology　2026/09/29

    DOI： 10.1007/s10384-026-01415-3 　

    More details Close

    PURPOSE: To identify risk factors for relapse in patients with myelin oligodendrocyte glycoprotein antibody-associated optic neuritis (MOG-ON) during the onset event. STUDY DESIGN: Retrospective cohort study. METHODS: We included 44 eyes of 44 Japanese patients with MOG-ON (median age 40.0 years [interquartile range 23.5-54.0]; male to female ratio 16:28) who visited Tohoku University Hospital between August 2013 and December 2024. We compared patient background characteristics; ophthalmic findings, including optical coherence tomography parameters; laboratory findings, including hematological, biochemical, and immunological parameters; anti-MOG antibody titers; and contrast-enhanced orbital MRI findings at baseline in relapse and non-relapse groups. Relapse risk was evaluated using a Kaplan-Meier survival analysis and a Cox proportional hazards regression. RESULTS: Nine of 44 (20.5%) patients relapsed during follow-up. The Kaplan-Meier analysis showed lower relapse-free survival in patients without eye-movement pain, those with a lower serum IgG level, and those with a thinner macular retinal nerve fiber layer (mRNFL; log-rank P=0.013, 0.049, and 0.040, respectively). In the age- and sex-adjusted Cox proportional hazards analysis, relapse risk was significantly associated with absence of eye-movement pain (hazard ratio [HR] 5.58, 95% confidence interval [CI] 1.35-23.04; P=0.018), a lower serum IgG level (HR 0.55, 95% CI 0.30-1.00; P=0.048), and a higher anti-MOG antibody titer (HR 1.98, 95% CI 1.05-3.71; P=0.034). CONCLUSION: Baseline absence of eye-movement pain, lower serum IgG level, and higher anti-MOG antibody titer were associated with relapse risk in patients with MOG-ON. A thinner mRNFL may represent a potential marker of relapse-related outcomes.

  2. Detection of Glaucomatous Visual Fields Using a Newly Developed Device with Retinal Projection Technology Peer-reviewed

    Satoru Tsuda, Hiroshi Kunikata, Makoto Ishikawa, Airi Takagi, Takeshi Yabana, Mitsuru Suzuki, Mitsuru Sugawara, Seiji Morino, Toru Nakazawa

    The Tohoku Journal of Experimental Medicine　2025

    Publisher: Tohoku University Medical Press

    DOI： 10.1620/tjem.2025.j032 　

    ISSN： 0040-8727

    eISSN： 1349-3329

  3. Relationship between corneal hysteresis and the site of damage to peripapillary retinal nerve fibre layer thickness in open-angle glaucoma. International-journal Peer-reviewed

    Yoko Takeda, Akiko Hanyuda, Naoki Takahashi, Kazuko Omodaka, Takahiro Ninomiya, Naoki Kiyota, Satoru Tsuda, Yu Yokoyama, Noriko Himori, Airi Takagi, Toru Nakazawa

    Scientific reports　14　(1)　26329-26329　2024/11/01

    DOI： 10.1038/s41598-024-76187-2 　

    More details Close

    Corneal hysteresis (CH) is associated with glaucomatous structural changes. We retrospectively investigated the association between CH and the regional circumpapillary retinal nerve fibre layer thickness (cpRNFLT) in 419 eyes of 419 patients with normal-tension glaucoma (NTG) and primary open-angle glaucoma (POAG). CH was used as the explanatory variable, and cpRNFLT (total and quadrant) was used as the dependent variable. Standardized β coefficients were compared both overall and between the NTG and POAG groups. Multiple regression analysis with CH as the explanatory variable and cpRNFLT parameters as the dependent variables suggested that even after adjusting for age, sex, intraocular pressure (IOP), axial length, and central corneal thickness, all areas of the cpRNFLT were significantly associated with CH, except for the nasal quadrant. In the stratified analysis by glaucoma type, a positive relationship between CH and regional cpRNFLT tended to be maintained in the NTG group but not in the POAG group (P = 0.060 for interaction). Additionally, in the NTG group, the CH-inferior cpRNFLT relationship was particularly strong in the less-IOP fluctuation group. These results suggest that CH may be a potential predictor of anatomical vulnerability around the optic nerve, particularly enhancing the inferior regions of NTG.

  4. Evaluation and Statistical Analysis for The Acute-phase Treatment of COVID-19 Peer-reviewed

    Airi TAKAGI, Shih-Wei Chiu, Takayo SUZUKI, Miyuki ISHIGURO, Yuko YAMADA, Takuhiro YAMAGUCHI, Shin TAKAYAMA

    Kampo Medicine　75　(3)　251-256　2024

    Publisher: Japan Society for Oriental Medicine

    DOI： 10.3937/kampomed.75.251 　

    ISSN： 0287-4857

    eISSN： 1882-756X

  5. Review of Clinical Research Articles on Kampo Medicines and Oral Antiviral Drugs for Acute-phase Treatment of COVID-19 Peer-reviewed

    Airi TAKAGI, Shin TAKAYAMA

    Kampo Medicine　75　(2)　168-175　2024

    Publisher: Japan Society for Oriental Medicine

    DOI： 10.3937/kampomed.75.168 　

    ISSN： 0287-4857

    eISSN： 1882-756X

  6. Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial. International-journal Peer-reviewed

    Shin Takayama, Takao Namiki, Ryutato Arita, Rie Ono, Aikiko Kikuchi, Minoru Ohsawa, Natsumi Saito, Satoko Suzuki, Hajime Nakae, Seiichi Kobayashi, Tetsuhiro Yoshino, Tomoaki Ishigami, Koichiro Tanaka, Airi Takagi, Takuhiro Yamaguchi, Tadashi Ishii, Akito Hisanaga, Kazuo Mitani, Takashi Ito

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　2023/07/26

    DOI： 10.1016/j.jiac.2023.07.013 　

    More details Close

    We previously reported the finding of symptom relief in a randomized controlled trial with the combined use of kakkonto and shosaikotokakikyosekko added to conventional treatment in patients with coronavirus disease 2019 (COVID-19). For further evaluation, we performed post hoc analysis focused on symptom disappearance without recurrence, to determine a clearer effect of Kampo medicine. Patients with mild and moderate COVID-19 were randomly allocated to a control group receiving symptomatic therapy or a Kampo group receiving kakkonto (2.5 g) with shosaikotokakikyosekko (2.5 g) three times daily in addition to symptomatic therapy. The data of 161 patients (Kampo group, n = 81; control group, n = 80) were analyzed post hoc for the time to symptom disappearance. Kaplan-Meier and Cox proportional hazard estimates of disappearance of symptoms showed that all and each symptom targeted in this study disappeared faster in the Kampo group than in the control group, although not statistically significant (all symptomatic cases; hazard ratio [HR] 3.73, 95% confidence interval [CI] 0.46-29.98, log-rank p = 0.1763). In a supplemental assessment using covariate adjustment and competing risk analysis, fever disappeared faster in the Kampo group than in the control group (all symptomatic cases, HR 1.62, 95% CI 0.99-2.64, p = 0.0557; unvaccinated cases, HR 1.68, 95% CI 1.00-2.83, p = 0.0498) and shortness of breath disappeared significantly faster in Kampo group than in control group (all symptomatic cases, HR 1.92, 95% CI 1.07-3.42, p = 0.0278; unvaccinated cases, HR 2.15, 95% CI 1.17-3.96, p = 0.0141). These results demonstrate the advantages of Kampo treatment for acute COVID-19.

  7. Performance of Bayesian Propensity Score Adjustment for Estimating Causal Effects in Small Clinical Trials Peer-reviewed

    Airi Takagi, Takuhiro Yamaguchi

    Open Journal of Statistics　13　(1)　2023/02

  8. Multicenter, randomized controlled trial of traditional Japanese medicine, kakkonto with shosaikotokakikyosekko, for mild and moderate coronavirus disease patients. Peer-reviewed

    Takayama S, Namiki T, Arita R, Ono R, Kikuchi A, Ohsawa M, Saito N, Suzuki S, Nakae H, Kobayashi S, Yoshino T, Ishigami T, Tanaka K, Nochioka K, Takagi A, Mimura M, Yamaguchi T, Ishii T, Hisanaga A, Mitani K, Ito T

    Front Pharmacol.　Nov 9　(13)　2022

    DOI： 10.3389/fphar.2022.1008946 　

    eISSN： 1663-9812

  9. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial Peer-reviewed

    Shin Takayama, Takao Namiki, Takashi Ito, Ryutaro Arita, Hajime Nakae, Seiichi Kobayashi, Tetsuhiro Yoshino, Tomoaki Ishigami, Koichiro Tanaka, Mosaburo Kainuma, Kotaro Nochioka, Airi Takagi, Masaru Mimura, Takuhiro Yamaguchi, Tadashi Ishii

    Trials　21　(1)　2020/12

    Publisher: Springer Science and Business Media LLC

    DOI： 10.1186/s13063-020-04746-9 　

    eISSN： 1745-6215

    More details Close

    Abstract Objectives We aimed to test our hypothesis that additional administration of traditional Japanese (Kampo) medicine, kakkonto (kakkon-to: KT) and shosaikotokakikyosekko (sho-saiko-to-ka-kikyo-sekko: SSKKS), is more effective in relieving symptoms and preventing the onset of severe infection in mild-to-moderate COVID-19 patients compared to those treated only with conventional treatment. Trial design The study is designed as a multi-center, interventional, parallel-group, randomized (1:1 ratio), investigator-sponsored, two-arm study. Participants Patients and inpatients will be recruited from 8 Japanese academic and non-academic hospitals. The inclusion and exclusion criteria are as follows: Inclusion criteria:Diagnosed as positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clinical stages of mild-to-moderate COVID-19 Symptomatic ≥ 20 years of age Male or female Ability to communicate in Japanese Outpatients and inpatients Provided informed consent Exclusion criteria:Difficulty in providing informed consent due to dementia, psychosis, or psychiatric symptoms Allergic to Kampo or Western medicines used in this study Pregnant and lactating Unable to follow up Participating in another clinical trial or interventional study Hypokalemic or taking oral furosemide or steroids Determined unsuitable for this study by the physician Intervention and comparator Patients in the control group will receive conventional treatment with antipyretics, painkillers, or antitussives for symptoms that occurred after they contracted the SARS-CoV-2 infection. Patients in the Kampo group will receive 2.5 g of KT (TJ-1@TSUMURA and Co.) and 2.5 g of SSKKS (TJ-109@TSUMURA and Co.) 3 times a day, orally, for 14 days in addition to the conventional treatment as mentioned above. Main outcomes The number of days till at least one of the symptoms (fever, cough, sputum, malaise, shortness of breath) improves in the first 14 days of treatment. To assess the cough, sputum, malaise, and shortness of breath, a numeric rating scale will be used to define improvement in terms of a 2-point decrease in the number of days from the start of treatment for at least 2 days. Fever will be defined as an improvement when the temperature is less than 37 °C. Randomization Patients are randomized (1:1 ratio) to each group using the minimization method, with balancing of the arms with severity of disease stage and patient age (< 65, 65 to < 75, or ≥ 75 years). Computer-generated random numbers will be used for the minimization method. Blinding (masking) Open-label with no blinding Numbers to be randomized (sample size) The main research hypothesis of this study is that the combination of Kampo medicine and conventional treatment will significantly improve the patients’ symptoms (fever, fatigue, cough, sputum, and shortness of breath) during the first 14 days of treatment as compared with conventional treatment alone. Concerning the analysis of the primary endpoint, the duration of time before improvement of at least one of the common cold-like symptoms (fever, malaise, cough, sputum, and shortness of breath) will be estimated using the Kaplan-Meier method, and the survival curves will be compared between groups using the log-rank test. Assuming this method of analysis and based on previous studies reporting the efficacy of Kampo medicine for COVID-19 and H1N1 influenza patients, the median survival time in the Kampo medicine group is estimated as 3 days; this time will be 1.5 times longer in the control group. Assuming a one-sided significance level of 5%, a power of 70%, and an allocation ratio of 1:1, the required sample size is calculated as 126 cases. To compensate for a loss in follow-up, we plan to include 150 cases in both groups (Kampo group = 75, control group = 75). Trial status Protocol version 1.2 as of August 20, 2020 Recruitment start (expected): October 1, 2020 Recruitment finish (expected): October 31, 2023 Trial registration Japan Registry of Clinical Trials (jRCT) jRCTs021200020. Registered on August 25, 2020 Full protocol The full protocol is attached as an additional file and is accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

  10. Efficacy and Safety of Low-Molecular-Weight Heparin on Prevention of Venous Thromboembolism after Laparoscopic Operation for Gastrointestinal Malignancy in Japanese Patients: A Multicenter, Open-Label, Prospective, Randomized Controlled Trial Peer-reviewed

    Tamotsu Obitsu, Naoki Tanaka, Atsushi Oyama, Tatsuya Ueno, Masaaki Saito, Takuhiro Yamaguchi, Airi Takagi, Toshiki Rikiyama, Michiaki Unno, Takeshi Naitoh, Hiromune Shimamura, Takeshi Suto, Fumito Saijo, Junichiro Yamauchi, Koh Miura

    Journal of the American College of Surgeons　231　(5)　501-509e2　2020/11

    Publisher: Ovid Technologies (Wolters Kluwer Health)

    DOI： 10.1016/j.jamcollsurg.2020.08.734 　

    ISSN： 1072-7515

  11. Adjunctive antimicrobial chemotherapy based on hydrogen peroxide photolysis for non-surgical treatment of moderate to severe periodontitis: a randomized controlled trial Peer-reviewed

    Taro Kanno, Keisuke Nakamura, Kirika Ishiyama, Yasutomo Yamada, Midori Shirato, Yoshimi Niwano, Chie Kayaba, Koji Ikeda, Airi Takagi, Takuhiro Yamaguchi, Keiichi Sasaki

    SCIENTIFIC REPORTS　7　(1)　12247　2017/09

    DOI： 10.1038/s41598-017-12514-0 　

    ISSN： 2045-2322

  12. Development and evaluation of an electromagnetic hypersensitivity questionnaire for Japanese people Peer-reviewed

    Sachiko Hojo, Mikiko Tokiya, Masami Mizuki, Mikio Miyata, Kumiko T. Kanatani, Airi Takagi, Naomi Tsurikisawa, Setsuko Kame, Takahiko Katoh, Takuya Tsujiuchi, Hiroaki Kumano

    BIOELECTROMAGNETICS　37　(6)　353-372　2016/09

    DOI： 10.1002/bem.21987 　

    ISSN： 0197-8462

    eISSN： 1521-186X

  13. OCT-Based Quantification and Classification of Optic Disc Structure in Glaucoma Patients Peer-reviewed

    Naoko Takada, Kazuko Omodaka, Tsutomu Kikawa, Airi Takagi, Akiko Matsumoto, Yu Yokoyama, Yukihiro Shiga, Kazuichi Maruyama, Hidetoshi Takahashi, Masahiro Akiba, Toru Nakazawa

    PLOS ONE　11　(8)　e0160226　2016/08

    DOI： 10.1371/journal.pone.0160226 　

    ISSN： 1932-6203

  14. Computation of induced electric field for the sacral nerve activation Peer-reviewed

    Akimasa Hirata, Junya Hattori, Ilkka Laakso, Airi Takagi, Takuo Shimada

    PHYSICS IN MEDICINE AND BIOLOGY　58　(21)　7745-7755　2013/11

    DOI： 10.1088/0031-9155/58/21/7745 　

    ISSN： 0031-9155

    eISSN： 1361-6560

  15. 「口腔ケア・マネジメントの確立」簡易・迅速に評価可能な口腔内細菌数測定装置の開発

    菊谷武, 濱田了, 高木愛理, 稲口哲也

    口腔ケア・マネジメントの確立 平成19年度 総括研究報告書 (厚生労働科学研究費補助金長寿科学総合研究事業)　26-31　2008

  16. A multicellular spheroid array to and viability realize spheroid formation, culture, assay on a chip Peer-reviewed

    Yu-suke Torisawa, Airi Takagi, Yuji Nashimoto, Tomoyuki Yasukawa, Hitoshi Shiku, Tomokazu Matsue

    BIOMATERIALS　28　(3)　559-566　2007/01

    DOI： 10.1016/j.biomaterials.2006.08.054 　

    ISSN： 0142-9612

    eISSN： 1878-5905

  17. Metabolic and enzymatic activities of individual cells, spheroids and embryos as a function of the sample size Peer-reviewed

    H Shiku, YS Torisawa, A Takagi, S Aoyagi, H Abe, H Hoshi, T Yasukawa, T Matsue

    SENSORS AND ACTUATORS B-CHEMICAL　108　(1-2)　597-602　2005/07

    DOI： 10.1016/j.snb.2004.12.030 　

    ISSN： 0925-4005

  18. A multicellular spheroid-based drug sensitivity test by scanning electrochemical microscopy Peer-reviewed

    YS Torisawa, A Takagi, H Shiku, T Yasukawa, T Matsue

    ONCOLOGY REPORTS　13　(6)　1107-1112　2005/06

    ISSN： 1021-335X

Show all ︎Show first 5

Misc. 1

  1. Association Between Disc Hemorrhage and Optic Disc Blood Flow in Eyes with Open-Angle Glaucoma

    Naoki Takahashi, Airi Takagi, Yoko Takeda, Takahiro Ninomiya, Sharma Parmanand, Satoru Tsuda, Toru Nakazawa

    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE　66　(8)　2025/06

    ISSN： 0146-0404

    eISSN： 1552-5783

Presentations 20

  1. 急性期治療に対する臨床評価と統計解析について Invited

    高木愛理, 邱士韡, 川邉庸介, 阿部歩実, 鈴木貴世, 石黒美由希, 板野豊江, 山田優子, 桑原安輝子, 高山真, 山口拓洋

    第73回日本東洋医学会学術総会 学会特別企画 COVID-19学会主導研究により得られた経験と今後の展開　2023/06/16

  2. データセンターの役割（データマネジメント、モニタリング） Invited

    鈴木貴世, 川邉庸介, 阿部歩実, 石黒美由希, 板野豊江, 高木愛理, 邱士韡, 山田優子, 桑原安輝子, 高山真, 山口拓洋

    第73回日本東洋医学会学術総会 学会特別企画 COVID-19学会主導研究により得られた経験と今後の展　2023/06/16

  3. 化学物質過敏・電磁過敏の合併の疑いがある 気管支喘息患者の臨床所見の特徴

    北條祥子, 釣木澤尚実, 金谷久美子, 水越 厚史, 高木愛理, 黒岩 義之

    第31回日本臨床環境医学会学術集会　2023/06

  4. Risk-based approachを実装した 研究開始前モニタリングの有効性の検討

    川邉 庸介, 阿部 歩実, 高木 愛理, 鈴木 貴世, 石黒 美由希, 板野 豊江, 髙田宗典, 高山 真, 山口 拓洋

    日本臨床試験学会第14回学術集会総会　2023/02

  5. COVID-19 感染拡大前後のデータセンター業務の比較と品質マネジメントシステム

    木村 淳也, 山田 優子, 髙田 宗典, 鈴木 貴世, 金津 さおり, 日野 聡, 泉 正之, 阿部 歩実, 遠藤 千代, 嶋田 南, 池田 鈴香, 川邉 庸介, 高木 愛理, 邱 士韡, 川上 貴弘, 務台 悠輝, 山口 拓洋, 張替 秀郎

    日本臨床試験学会第12回学術集会総会　2021/02/12

  6. 医師主導治験におけるアカデミアでのCDISC対応経験

    邱 士韡, 高木, 愛理, 高田, 宗典, 鈴木, 貴世, 日野, 聡, 木村, 淳也, 山口, 拓洋, 下川 宏明

    ARO協議会第7回学術集会　2019/09

  7. 医師主導治験におけるラジカル殺菌歯周病治療器の臨床効果の検証:無作為化比較試験

    佐々木啓一, 菅野太郎, 中村圭祐, 石山希里香, 山田康友, 白土翠, 庭野吉己, 萱場千恵, 池田浩治, 高木愛理, 山口拓洋

    第62回春季日本歯周病学会学術大会　2019

  8. Bayesian evidence synthesis and assessment techniques across longitudinal time points

    Airi Takagi, Takuhiro Yamaguchi

    International Society for Biopharmaceutical Statistics　2019

  9. CRF作成業務における CDISC標準の取り組み

    山田 優子, 髙橋, 史朗 邱, 士韡, 高木, 愛理, 京谷, 恵里, 鈴木, 貴世, 木村, 淳也, 山口, 拓洋, 下川 宏明

    日本臨床試験学会第9回学術集会総会　2018/02

  10. AROにおける解析プロセスの標準化と効率向上～TLFを優先に～

    Shih-Wei Chiu, 高橋史朗, 高木愛理, 山口拓洋, 下川宏明

    日本臨床試験学会第9回学術集会総会　2018/02

  11. Use of historical data in non-inferiority trials

    Airi Takagi

    Japanese Joint Statistical Meeting　2017

  12. 緑内障患者における酸化ストレスと視野

    國方彦志, 檜森紀子, 川崎良, 志賀由己浩, 面高宗子, 高木愛理, 中澤徹

    日本酸化ストレス学会学術集会　2016

  13. Performance Comparison between Bayesian Estimation Method and Maximum Likelihood Method in Estimation of Propensity Scores

    Airi Takagi

    Japanese Joint Statistical Meeting　2016

  14. 光干渉断層計を利用した生活不自由度の予測の試み

    国松志保, 面高宗子, 高津育美, 岸南希, 鈴鴨よしみ, 小野峰子, 高木愛理, 中澤徹

    第26回日本緑内障学会　2015

  15. 口腔内細菌採取は口腔乾燥の影響を受ける

    田代晴基, 菊谷武, 田村文誉, 片桐陽香, 久野彰子, 平林正裕, 濱田了, 高木愛理, 稲口哲也, 吉田光由, 米山武義

    日本老年歯科医学会総会・学術大会　2009

  16. 細菌数による口腔衛生評価方法の確立(第一報)-評価用細菌数測定器の開発-

    濱田了, 高木愛理, 稲口哲也, 菊谷武, 田村文誉, 古西清司, 高橋幸裕, 矢島彩子, 吉田光由, 米山武義

    老年歯科医学 (Japanese Journal of Gerodontology)　2008

  17. 口腔衛生状態評価用細菌数測定器の開発(第二報)モニタリング機器としての有用性の検討

    菊谷武, 田村文誉, 戸原雄, 片桐陽香, 濱田了, 高木愛理, 稲口哲也, 古西清司, 高橋幸裕, 矢島彩子, 吉田光由, 米山武義

    老年歯科医学 (Japanese Journal of Gerodontology)　2008

  18. 誘電泳動インピーダンス計測法を利用した口腔内細菌数測定装置の開発

    濱田了, 高木愛理, 稲口哲也, 菊谷武, 田村文誉, 古西清司, 高橋幸裕, 矢島彩子, 米山武義, 末廣純也

    第47回日本生体医工学会大会　2008

  19. 癌細胞スフェロイドのon chip評価デバイスの構築

    高木愛理, 鳥沢勇介, 安川智之, 珠玖仁, 末永智一

    電気化学秋季大会　2005

  20. 肝癌細胞スフェロイドの電気化学的活性評価とチップ化の検討

    高木愛理, 鳥沢勇介, 安川智之, 珠玖仁, 末永智一

    化学系学協会東北大会　2004

Show all Show first 5

Industrial Property Rights 10

  1. 電気治療器および電極パッドの劣化判定方法

    高木 愛理

    Property Type: Patent

  2. 排尿障害治療装置

    高木 愛理

    Property Type: Patent

  3. 排尿障害治療器

    高木 愛理

    Property Type: Patent

  4. 排尿障害治療器

    高木 愛理, 久本 隆

    Property Type: Patent

  5. 細菌検査装置

    濱田 了, 稲口 哲也, 高木 愛理

    Property Type: Patent

  6. 細菌検査装置

    濱田 了, 稲口 哲也, 高木 愛理

    特許第5407539号

    Property Type: Patent

  7. 電極基板とそれを用いた微生物・微粒子測定装置

    高木 愛理, 尾崎 亘彦, 濱田 了

    特許第5205889号

    Property Type: Patent

  8. チャンバを有する流路部位を含む基板、およびそれを含む多段送液装置

    尾崎 亘彦, 高木 愛理

    Property Type: Patent

  9. 排尿障害治療器

    高木 愛理, 久本 隆

    特許第5548688号

    Property Type: Patent

  10. チャンバを有する流路部位を含む基板、およびそれを含む多段送液装置

    尾崎 亘彦, 高木 愛理

    特許第4918589号

    Property Type: Patent

Show all Show first 5

Research Projects 1

  1. 臨床品質マネジメントにおける機械学習を用いた革新的リスクコントロール手法の開発

    高木 愛理

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 若手研究

    Institution: 東北大学

    2024/04/01 - 2028/03/31